Abstract Number: 1753 • ACR Convergence 2024
A Phase 1, Multicenter, Open-Label Study to Establish the Preliminary Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of CC-97540 (BMS-986353), a CD19-directed CAR T Cell Therapy Manufactured Using a Next-generation Process, for Severe, Refractory Autoimmune Diseases
Background/Purpose: CD19 is an appealing therapeutic target due to its ubiquitous expression on B cells and plasmablasts, which play a key role in the pathogenesis…Abstract Number: 1793 • ACR Convergence 2024
SLE Patient Serum and SLE-associated Danger Signals Impair Efferocytosis in Human Macrophages
Background/Purpose: Efficient clearance of apoptotic cells, known as efferocytosis, plays a pivotal role in maintaining self-tolerance. Dysfunction in efferocytosis is implicated in the pathogenesis of…Abstract Number: 1839 • ACR Convergence 2024
PPP2R3C Overexpression Suppresses TCR -mediated CD4+ T Cell Abnormal Activation in Systemic Lupus Erythematosus via JNK and AKT-mTOR Pathways
Background/Purpose: Systemic Lupus Erythematosus (SLE) is distinguished by immune system dysfunction, leading to heightened activation of T and B cells. This increased activity leads to…Abstract Number: 2049 • ACR Convergence 2024
Genetically Proxied Glucose‑lowering Drug Target and Risk of Immune Mediated Inflammatory Disease: A Mendelian Randomization Study
Background/Purpose: There are conflicting findings on the relationship between glucose-lowering drugs and risk of development of immune mediated inflammatory diseases (IMIDs). The study aimed to…Abstract Number: 2377 • ACR Convergence 2024
Impact of Neighborhood Area Deprivation Index on Outcomes in Lupus Patients in Bronx, NY
Background/Purpose: Studies have demonstrated that socioeconomic status (SES) significantly influences outcomes of patients with SLE.1 Traditionally, tools such as income, education, occupation, and housing have…Abstract Number: 2396 • ACR Convergence 2024
PROMISing Outcomes: Understanding the Concordance Between Provider-assessment and Patient-reported Disease Activity in SLE
Background/Purpose: SLE-related outcomes are traditionally assessed by clinician-derived measures. However, these assessments often do not fully capture how patients experience their disease. We assessed the alignment…Abstract Number: 2414 • ACR Convergence 2024
A Retrospective Comparative Analysis of Cardiovascular Risk Factors, Atherosclerotic Cardiovascular Disease and Statin Use as Secondary Prevention in a Cohort of Patients with Systemic Lupus Erythematosus versus Without Rheumatological Disease from a Single-Center Patient Registry
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have increased prevalence of cardiovascular risk factors (RFs), which predispose to higher risk of premature atherosclerotic cardiovascular disease…Abstract Number: 2430 • ACR Convergence 2024
Dapirolizumab Pegol Impacts Important Immunologic Pathways in Systemic Lupus Erythematosus: Pharmacodynamic Analysis of T Cell and Antigen Presenting Cell Pathways from a Phase 2b Trial
Background/Purpose: CD40-CD40L interactions play a pivotal role in systemic lupus erythematosus (SLE) pathogenesis by orchestrating a range of immune and inflammatory responses involving B cells,…Abstract Number: 2576 • ACR Convergence 2024
Glucagon-Like Peptide-1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients with Systemic Lupus Erythematosus and Lupus Nephritis
Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are hypoglycemic agents with well-established cardioprotective properties and emerging data for kidney-protective benefits in patients with type 2 diabetes…Abstract Number: 2658 • ACR Convergence 2024
Hypovitaminosis D in Lupus Nephitis
Background/Purpose: The prevalence of vitamin D deficiency is higher in patients with systemic lupus erythematosus (SLE) compared to the healthy population, and recent studies have…Abstract Number: 0008 • ACR Convergence 2024
Preclinical Development and Manufacturability of KYV-201, an Investigational Allogeneic Anti-CD19 Chimeric Antigen Receptor T Cell for the Treatment of Autoimmune Disease
Background/Purpose: Autologous anti-CD19 chimeric antigen receptor (CAR) T cells show early clinical evidence of safety and efficacy for treating several autoimmune diseases (Müller F. N Engl…Abstract Number: 0106 • ACR Convergence 2024
IgM and IgG Phosphatidylserine Antibody Detection May Improve Classification Accuracy of SLE and APS
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune coagulopathy that causes microvascular and macrovascular thrombosis in both venous and arterial systems. This can occur as a…Abstract Number: 0179 • ACR Convergence 2024
Bridging the Gap: Enhancing Diversity in Lupus Clinical Trials Through Investigator and Research Staff Engagement
Background/Purpose: Lupus disproportionately affects diverse racial and ethnic minority populations, yet there is a significant disparity between those affected and those enrolled in clinical trials.…Abstract Number: 0211 • ACR Convergence 2024
Characteristics of Hospitalizations and Outpatient Follow-up for Patients with SLE at an Academic Hospital Setting in Austin, Texas
Background/Purpose: Patients with SLE have high rates of hospitalizations annually and require careful coordination of care in both the inpatient and outpatient setting. Prior analyses…Abstract Number: 0427 • ACR Convergence 2024
Association of Menopause and Systemic Rheumatic Disease Severity in Peri-Menopausal and Menopausal Women with Systemic Rheumatic Disease
Background/Purpose: The relationship between menopause and systemic rheumatic disease (SRD) severity in women with SRDs is poorly understood. Few studies evaluating this association suggest worsening…
- « Previous Page
- 1
- …
- 38
- 39
- 40
- 41
- 42
- …
- 181
- Next Page »